Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2600/00—Oligonucleotides characterized by their use
  • C12Q2600/156—Polymorphic or mutational markers

Definitions

• a determination of which medications to use to treat a patient in need of treatment with an IM would be based on the results of the determination of the nature of the nucleotide pairs at position -511 in the IL-1 ⁇ gene present in the patient.
• the odds ratio indicates that patients are 5.67 (95% confidence limits: 1.20-9.01) times more likely to have an increase in total blood cholesterol levels to a final concentration >240 mg/dL when treated with the RAD/NEORAL ® regimen if they contain a T at position (-511) in the IL-1 ⁇ gene promoter, or 7.23 (95% confidence limits: 1.20-9.01 ) times more likely to have an increase in total blood cholesterol levels to a final concentration >240 mg/dL when treated with the RAD/NEORAL ® regimen if they contain a C at position (-31) in the IL-1 ⁇ gene promoter.
• TATAAAA TATA box sequence
• An allele-specific oligonucleotide primer of the invention has a 3' terminal nucleotide, or preferably a 3' penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present. Allele-specific oligonucleotide primers hybridizing to either the coding or noncoding strand are contemplated by the invention.
• An ASO primer for detecting IL-1 ⁇ gene polymorphisms could be developed using techniques known to those of skill in the art.
• the polymorphism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification.
• a site may be positively determined to be either guanine or cytosine for all individual homozygous at that site, or both guanine and cytosine, if the individual is heterozygous at that site.
• the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).
• Polymorphism Information concerning one or more of the following for a specific gene data location of polymorphic sites; sequence variation at those sites; frequency of polymorphisms in one or more populations; the different genotypes and/or haplotypes determined for the gene; frequency of one or more of these genotypes and/or haplotypes in one or more populations; any known association(s) between a trait and a genotype or a haplotype for the gene.
• Polymorphism A collection of polymorphism data arranged in a systematic or database methodical way and capable of being individually accessed by electronic or other means.
• the reference population represents the genetic variation in the population at a certainty level of at least 85%, preferably at least 90%, more preferably at least 95% and even more preferably at least 99%.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Wood Science & Technology (AREA)
• Analytical Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Pathology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Obesity (AREA)
• Transplantation (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Steroid Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=32043422

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (3)

Family Cites Families (6)

• 2003
  • 2003-09-29 BR BR0314552-2A patent/BR0314552A/pt not_active IP Right Cessation
  • 2003-09-29 US US10/529,613 patent/US7732134B2/en not_active Expired - Fee Related
  • 2003-09-29 PT PT03779798T patent/PT1549770E/pt unknown
  • 2003-09-29 AT AT03779798T patent/ATE389034T1/de active
  • 2003-09-29 DE DE60319719T patent/DE60319719T2/de not_active Expired - Lifetime
  • 2003-09-29 EP EP03779798A patent/EP1549770B1/en not_active Expired - Lifetime
  • 2003-09-29 JP JP2004539048A patent/JP4575775B2/ja not_active Expired - Fee Related
  • 2003-09-29 ES ES03779798T patent/ES2302959T3/es not_active Expired - Lifetime
  • 2003-09-29 CN CNB038233428A patent/CN100453650C/zh not_active Expired - Fee Related
  • 2003-09-29 WO PCT/EP2003/010798 patent/WO2004029618A2/en not_active Ceased
  • 2003-09-29 AU AU2003287955A patent/AU2003287955B2/en not_active Ceased
  • 2003-09-29 CA CA002500979A patent/CA2500979A1/en not_active Abandoned
• 2005
  • 2005-03-24 IL IL167639A patent/IL167639A/en not_active IP Right Cessation
• 2010
  • 2010-02-15 US US12/705,754 patent/US20100184798A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events